Clinical review report Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) (Gilead Sciences Canada, Inc.)
The objective of this report was to perform a systematic review of the beneficial and harmful effects of a Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) (400 mg / 100 mg / 100 mg) single-tablet regimen for the treatment of chronic hepatitis C (CHC) genotype 1, 2, 3, 4, 5, and 6 infection in adul...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa, Ontario :
Canadian Agency for Drugs and Technologies in Health
2018.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820281806719 |
| Sumario: | The objective of this report was to perform a systematic review of the beneficial and harmful effects of a Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) (400 mg / 100 mg / 100 mg) single-tablet regimen for the treatment of chronic hepatitis C (CHC) genotype 1, 2, 3, 4, 5, and 6 infection in adults who are direct-acting antiviral agent (DAA) treatment experienced. |
|---|---|
| Descripción Física: | 1 online resource (1 PDF file (66 pages)) : illustrations |
